{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"54.5","upperLimit":"68.4","value":"61.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"198"}],"units":"Participants"}],"description":"Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT: Complete Response (CR): Disappearance of all target and non-target lesions and no new lesions; Partial Response (PR): \\>= 30% decrease in the sum of diameters of Target Lesions (compared to baseline) and no new lesions. ORR is the percentage of patients with at least 1 visit response of CR or PR (by independent central review) that was confirmed at least 4 weeks later, prior to progression or further anti-cancer therapy.","dispersionType":"95% Confidence Interval","groups":[{"description":"Phase II dose extension cohort in pre-treated EGFR T790M mutation positive patients in AZD9291 80mg tablet.","id":"OG000","title":"80mg AZD9291 Extension"}],"paramType":"NUMBER","populationDescription":"All patients in the 80mg AZD9291 extension part of the study (second line or later, EGFR T790M mutation positive by central testing) who received at least one dose of AZD9291 and had measurable disease (by independent central review) at baseline.","reportingStatus":"POSTED","timeFrame":"RECIST tumour assessments every 6 weeks from randomisation until objective disease progression, up to approximately 12 months (at the time of analysis)","title":"Objective Response Rate (ORR) for Extension Population","type":"PRIMARY","unitOfMeasure":"% of participants"}